Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.74), $0.01 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• UBS Reiterates Buy Rating on PVH Corp (PVH) on Strong Earnings Growth Potential